Halitosis
Conditions
Brief summary
Halitosis or bad breath is a problem affecting 30% of the world's population. There are many causes, and oral pathologies, including periodontitis, are the main etiology. In order to make a diagnosis, a clinical interview is necessary to distinguish true halitosis from psychological halitosis. In addition, a measurement of volatile sulfur compounds (VSC), the main molecules involved in bad breath, is necessary. This is done during the consultation by measuring the concentration of VSCs in exhaled air. However, few private practices or hospitals have the necessary equipment to measure VSC. As a result, patients are often obliged to travel long distances to obtain a consultation including this specific VSC analysis. The aim of this study is to evaluate the stability of VSC values obtained in gaseous samples up to 7 days after sampling, in order to assess the clinical relevance of analyzing samples at a distance from sampling. The clinical aim is to determine whether self-sampling by the patient at home and extemporaneous analysis could be considered in the diagnosis of halitosis.
Interventions
OTHERGaseous sampling:
the subject is asked to aspirate the gaseous contents of his oral cavity using a 1ml plastic syringe.
Sponsors
University Hospital, Strasbourg, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult, male or female * Subject affiliated with a social health insurance plan * Able to understand the objectives and risks of the research and to give dated and signed informed consent * Subject presenting for consultation for diagnosis and treatment of periodontal pathology
Exclusion criteria
* Subject under safeguard of justice * Subject under guardianship or curatorship * Pregnancy or breast-feeding * Impossibility of giving the subject informed information (subject in emergency situation, difficulties in understanding the subject, etc.) * Subject currently included in another clinical research protocol or in an exclusion period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H2S measurement | Analysis will be made at Day 0 and Day 7 |
Countries
France
Outcome results
None listed